Over the past decade, it was gradually replaced by GnRH antagonist protocol, which is characterized by rapid suppression of LH with fewer injections and reduced risk of ovarian hyperstimulation syndrome (OHSS) [2]. The gene discussed is GNRH1; the disease is ovarian hyperstimulation syndrome.